Adalimumab as Treatment for Venous Thrombosis in Behçet's Syndrome: Comment on the Article by Emmi et al

View/Open
Date
2019-03-02
Author
Farisogullari, Bayram
Sari, Alper
Ayar, Sefika Nur
Kilic, Levent
Armagan, Berkan
Karadağ, Ömer
xmlui.mirage2.itemSummaryView.MetaData
Show full item record
Abstract
We read with interest the article by Emmi et al 1 regarding the effect of adalimumab (ADA)–based treatment versus disease‐modifying antirheumatic drug (DMARD) therapy for venous thrombosis in Behçet's syndrome (BS). Their findings add important data to help answer the difficult questions on the treatment of BS. However, there are some concerns.
URI
https://doi.org/10.1002/art.40795
https://pubmed.ncbi.nlm.nih.gov/30548210/
https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.40795
http://hdl.handle.net/11655/23569
xmlui.mirage2.itemSummaryView.Collections
xmlui.dri2xhtml.METS-1.0.item-citation
Farisogullari B, Sari A, Ayar SN, Kilic L, Armagan B, Karadag O. Adalimumab as Treatment for Venous Thrombosis in Behçet's Syndrome: Comment on the Article by Emmi et al. Arthritis Rheumatol. 2019 Apr;71(4):657. doi: 10.1002/art.40795. Epub 2019 Mar 2. PMID: 30548210.

The following license files are associated with this item:

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess